SELLAS Life Sciences Group, Inc.
No SEC Form 4 filings for $SLS in the last 30 days.
See all $SLS insider activity →Sellas Life Sciences Group (SLS) shares rose about 2% overnight after CEO Angelos Stergiou said he is “very bullish” on Phase 3 Regal trial data for galinpepimut-S (GPS) in AML. The trial has reached 78 of 80 events, with final analysis after the 80th. Stergiou said positive results could support NCCN recognition and cited prior survival projections.
SELLAS Life Sciences (SLS) shares were flat after-hours after reporting a narrower Q2 per-share loss. Net loss was $9.6M, or $0.05/share, vs $6.6M, or $0.07/share, a year earlier. Cash was $138.3M. Investors await the end of the REGAL trial “quiet period” tied to Galinpepimut-S (GPS), after reaching 80 deaths; no timeline given.
Vanguard Capital Management increased its stake in Sellas Life Sciences (SLS) by 9.3% to 8.23 million shares and held 15.69 million shares of ImmunityBio (IBRX) valued at $137.4 million, according to June 30 filings. SLS009 Phase 2 enrolled 28 of 80 patients, initial data due Q4. IBRX reported record Anktiva revenue and seeks label expansion.
Over the past 7 days, alphai's AI scored 5 news stories mentioning SLS (SELLAS Life Sciences Group, Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 1 bearish.
Recent SLS coverage spans financial news, technology and earnings.
Near-term sentiment tailwind for SLS tied to Regal trial progress and CEO’s NCCN-readout framing, but no new topline data yet.
Near-term trading hinges less on the earnings math and more on the timing and communications around the REGAL topline analysis window after the 80-event threshold.
Institutional accumulation plus a concrete Phase 2 enrollment milestone can support near-term sentiment, but it is not a new clinical result.
The article frames the stock as momentum-driven but valuation-stretched, using the reported loss and a high P/B multiple to highlight downside risk.
Near-term catalysts are tied to REGAL trial event timing (database lock and topline after the 80th event) and SLS009 Phase 2 topline timing in Q4 2026, alongside higher operating costs and cash runway signals.
alphai scores every news story that mentions SLS with an AI model for sentiment and relevance, and aggregates insider trades from SELLAS Life Sciences Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sellas Life Sciences Group (SLS) shares rose about 2% overnight after CEO Angelos Stergiou said he is “very bullish” on Phase 3 Regal trial data for galinpepimut-S (GPS) in AML. The trial has reached 78 of 80 events, with final analysis after the 80th. Stergiou said positive results could support NCCN recognition and cited prior survival projections.
6 min readSELLAS Life Sciences (SLS) shares were flat after-hours after reporting a narrower Q2 per-share loss. Net loss was $9.6M, or $0.05/share, vs $6.6M, or $0.07/share, a year earlier. Cash was $138.3M. Investors await the end of the REGAL trial “quiet period” tied to Galinpepimut-S (GPS), after reaching 80 deaths; no timeline given.
4 min readVanguard Capital Management increased its stake in Sellas Life Sciences (SLS) by 9.3% to 8.23 million shares and held 15.69 million shares of ImmunityBio (IBRX) valued at $137.4 million, according to June 30 filings. SLS009 Phase 2 enrolled 28 of 80 patients, initial data due Q4. IBRX reported record Anktiva revenue and seeks label expansion.
7 min readSimply Wall St reports SELLAS Life Sciences Group (SLS) drew renewed attention after its Q2 2026 results, showing a net loss of $9.61 million and updated loss per share from continuing operations. The stock closed at $11.05 and trades at a 20.2x price-to-book versus a 4.9x peer average and 2.4x industry average, despite reporting a $29.457 million loss and under $1 million revenue.
5 min readSELLAS Life Sciences Group, Inc. (SLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sls-202608118xkexhibit991.htm EX-99.1 Document Exhibit 99.1 SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update – Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Followi
4 min readSellas Life Sciences Group (SLS) shares rose more than 4% to $8.12, heading toward a fifth straight weekly gain. CEO Angelos Stergiou cited real-world MD Anderson data in elderly AML patients treated with intensive regimens, and said the results support the Phase 3 REGAL trial of GPS. REGAL had reached 78 events as of May 11, with two remaining before final analysis.
4 min readNebius Group (NBIS), Cisco Systems (CSCO), and Sellas Life Sciences Group (SLS) hit 52-week highs. Nebius reported Q1 revenue of $399M, up 684% YoY, and raised 2026 ARR guidance to $7B-$9B, plus access to up to 1.2 GW power for an AI facility. Cisco raised AI infrastructure order forecast to about $9B and reported Q3 revenue of $15.8B. SLS said its Phase 3 REGAL AML study is nearing a final event threshold and reported $107M+ cash.
4 min readState Street Corporation and related investment adviser subsidiaries filed a Schedule 13G for SELLAS Life Sciences Group Inc. As of 06/30/2026, they reported passive beneficial ownership of 12,996,558 common shares, about 7% of the outstanding class. The filing shows shared voting power over 12,677,559 shares and shared dispositive power over 12,996,558 shares.
2 min readSellas Life Sciences Group (SLS) shares rose about 2% to above $5 after CEO Angelos Stergiou said the company was invited to the EU Parliament’s Public Health Committee to discuss the EU Biotech Act and drug-approval policy. Investors also focus on its Phase 3 REGAL AML trial nearing an 80-event overall-survival threshold, plus a proposed 20M-share equity plan expansion.
6 min readSellas Life Sciences Group (SLS) shares rose in premarket trading after CEO Angelos Stergiou said GPS in its AML Phase 3 Regal trial has a “very good chance” to match or beat earlier survival results. Regal reached 78 events as of May 11, with two events left before final analysis. Company targets median overall survival of 12.6 months vs 8.1 months.
4 min read
